Analystreport

Castle Biosciences (NASDAQ:CSTL) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.

Castle Biosciences, Inc. - Common stock  (CSTL) 
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm Check Earnings Report